-
Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) GalleryLupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
411, 2021
Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
Slough, UK, 4 November 2021: Global pharma major Lupin today announces [...]
211, 2021
Register for the first #LivingDiabetesTogether webinar!
Living Diabetes together – Starting insulin Tuesday, November 9th, 2021 [...]
211, 2021
J&J Webinar Invitation: Children’s Healthcare: Overview & Guidance for Recommendation
Discover how to offer better support and guidance on children’s [...]
3009, 2021
System C acquires WellSky International
System C Healthcare (“System C”) is pleased to announce that [...]
